全文获取类型
收费全文 | 3274篇 |
免费 | 258篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 6篇 |
妇产科学 | 7篇 |
基础医学 | 158篇 |
口腔科学 | 21篇 |
临床医学 | 328篇 |
内科学 | 852篇 |
皮肤病学 | 8篇 |
神经病学 | 154篇 |
特种医学 | 33篇 |
外科学 | 119篇 |
综合类 | 643篇 |
预防医学 | 153篇 |
眼科学 | 12篇 |
药学 | 1010篇 |
10篇 | |
中国医学 | 77篇 |
肿瘤学 | 56篇 |
出版年
2024年 | 2篇 |
2023年 | 17篇 |
2022年 | 41篇 |
2021年 | 89篇 |
2020年 | 101篇 |
2019年 | 97篇 |
2018年 | 113篇 |
2017年 | 124篇 |
2016年 | 155篇 |
2015年 | 174篇 |
2014年 | 348篇 |
2013年 | 527篇 |
2012年 | 316篇 |
2011年 | 335篇 |
2010年 | 229篇 |
2009年 | 188篇 |
2008年 | 170篇 |
2007年 | 192篇 |
2006年 | 154篇 |
2005年 | 101篇 |
2004年 | 68篇 |
2003年 | 49篇 |
2002年 | 24篇 |
2001年 | 13篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1991年 | 1篇 |
排序方式: 共有3649条查询结果,搜索用时 15 毫秒
1.
动脉粥样硬化是导致心血管疾病及死亡的主要原因,严重危害人类健康。目前预防动脉粥样硬化
的机制众多,以调脂代谢降低炎症反应为基础较多。本文将近几年他啶类、贝特类、烟酸类以及中药等调脂药物
对预防动脉粥样硬化的药理作用以及临床应用研究现状做一综述。 相似文献
的机制众多,以调脂代谢降低炎症反应为基础较多。本文将近几年他啶类、贝特类、烟酸类以及中药等调脂药物
对预防动脉粥样硬化的药理作用以及临床应用研究现状做一综述。 相似文献
2.
他汀类药物对心血管的保护作用 总被引:6,自引:0,他引:6
他汀类药物(statins)被研制出来的最初目的是降低血脂,但是现在发现它不仅具有降低血脂的作用,还具有很多其他的作用包括改善内皮细胞功能的紊乱,提高内皮源性一氧化氮合成酶的生物活性,抑制血管平滑肌细胞的增殖,抗氧化作用,抗炎作用,降低血压,逆转心血管系统的重构。充分理解statins的多效性作用及机制有利于它更好的在临床中被应用于心血管系统的预防和治疗。 相似文献
3.
A. UNDAS M. CELINSKA-LÖWENHOFF T. LÖWENHOFF A. SZCZEKLIK 《Journal of thrombosis and haemostasis》2006,4(5):1029-1036
BACKGROUND: Aspirin increases fibrin clot porosity and susceptibility to lysis. It is unknown whether other drugs, in combination with aspirin, used in the treatment of coronary artery disease (CAD) might affect clot structure and resistance to lysis. AIM: The aim of the study was to assess the effects of statins, fibrates, or angiotensin-converting enzyme inhibitors (ACEIs) on fibrin clot properties. PATIENTS AND METHODS: In a randomized double-blind study, men with advanced CAD taking low-dose aspirin were assigned to receive one of the four drugs: simvastatin 40 mg day(-1) (n = 13), atorvastatin 40 mg day(-1) (n = 12), fenofibrate 160 mg day(-1) (n = 12), and quinapril 10 mg day(-1) (n = 11) for 28 +/- 2 days. Moreover, CAD patients (n = 13) taking aspirin (75 mg day(-1)) for 8 weeks were studied after additional 4 weeks on an open-label basis. Thirty men served as healthy controls. Plasma clot permeability and tissue plasminogen activator-induced fibrinolysis were evaluated at baseline and after drug administration. RESULTS: Permeability increased following the administration of simvastatin (by 20%; P = 0.01), atorvastatin (by 22%; P = 0.001), fenofibrate (by 16%; P = 0.02), and quinapril (by 13%; P = 0.04) like for aspirin (P < 0.001). Turbidity analysis showed that administration of any of the drugs was associated with higher maximum absorbancy, suggesting thicker fibers, and shorter fibrinolysis time (P < 0.001). Post-treatment reduction in lysis time correlated with an increase in clot porosity in all the groups (r from 0.42 to 0.61; P from 0.01 to 0.001). CONCLUSIONS: Statins, fibrates, and ACEIs may increase plasma clot permeability and susceptibility to fibrinolysis in CAD patients receiving aspirin. This novel antithrombotic mechanism might contribute to clinical benefits of the drugs tested. 相似文献
4.
The Lipid-regulating Effects of Atorvastatin on Type 2 Elder Diabetes Patients with Hyperlipidemia 总被引:1,自引:0,他引:1
Inthisstudy,theeffectofatorvastatinonlipidmetabolism ,especiallysLDL ,intype 2elderdiabetespatientswithhyperlipidemiawasstudy .Theresultswerepresentedasfollows.1 SUBJECTSANDMETHODS1 1 SubjectsThesubjectsincluded 2 6patientswithtype 2elderdiabetesandhyp… 相似文献
5.
目的:应用高频超声观察冠心病(CAD)患者,经阿托伐他汀治疗后对肱动脉内皮依赖性舒张功能(EDD)的改善作用。方法:经冠脉造影(CAG)确诊为CAD患者59例,利用高频超声血管技术检测阿托伐他汀对CAD患者治疗前后肱动脉EDD的疗效。结果:阿托伐他汀治疗2年后,EDD比治疗前有明显改善(P〈0.05),与对照组相比无显著性差异(P〉0.05)。常规治疗组治疗2年后,EDD无明显改善(P〉0.05),与阿托伐他汀组治疗后及对照组相比差异有显著性(P〈0.05)。结论:阿托伐他汀具有改善EDD的作用。 相似文献
6.
阿托伐他汀治疗混合型高脂血症的疗效观察 总被引:5,自引:2,他引:3
目的 评价阿托伐他汀治疗混合型高脂血症的疗效。方法 将 6 2例高脂血症患者随机分为A、B两组 ,A组 32例 ,给予阿托伐他汀 10mg d,4周后血清胆固醇未下降 10 %者 ,可增量到 2 0mg d ;B组 30例 ,给予氟伐他汀2 0mg d,4周后血清胆固醇未下降 10 %者 ,可加量到 4 0mg d,两组均治疗 8周 ,观察降脂疗效。结果 阿托伐他汀组 ,总胆固醇 (TC)从 (6 83± 0 86 )mmol L降至 (4 6 8± 0 84 )mmol L ;甘油三酯 (TG)从 (3 16± 0 81)mmol L降至(2 0 4± 0 76 )mmol L ;低密度脂蛋白胆固醇 (LDL -C)从 (3 94± 1 2 2 )mmol L降至 (2 32± 0 77)mmol L (P均 <0 0 1)。两组降脂疗效间差别无显著性意义 (P >0 0 5 ) ,但治疗后两组患者的TG、LDL -C含量间差别有显著性意义(P <0 0 5 )。结论 阿托伐他汀有明显降TC、LDL -C、TG的作用 ,可用于混合型高脂血症的治疗 相似文献
7.
Massimo Chello Costanza Goffredo Giuseppe Patti Dario Candura Rosetta Melfi Stefano Mastrobuoni Germano Di Sciascio Elvio Covino 《European journal of cardio-thoracic surgery》2005,28(6):805-810
Objective: Endothelial dysfunction represents a critical early component of organ injury following cardiopulmonary bypass. Recent studies demonstrate that the treatment with atorvastatin is associated with a significant improvement of endothelial function independently of its efficacy on cholesterol levels. Therefore, we investigated the effects of preoperative atorvastatin treatment on endothelium function after coronary surgery. Methods: Forty patients undergoing coronary surgery were randomized to treatment with atorvastatin (20 mg/die; N = 20) or placebo (N = 20) 3 weeks before surgery. Twenty normal patients served as control group. The flow-mediated dilations (FMD) of the brachial artery after both reactive hyperemia (endothelium dependent) and nitroglycerin administration (endothelium independent) were evaluated at baseline, at 48 h, and 5 days postoperatively. Results: At baseline, the endothelium-dependent FMD was significantly attenuated in coronary versus normal patients (normal 10.3 ± 1.8% vs coronary 4.1 ± 1.6%, p < 0.01). At 48 h postoperatively all patients exhibited a reduced FMD compared with baseline values: the endothelium-dependent dilatation showed a drop of 60.1 + 15% in the patients of the placebo group compared with 45.8 + 16.6% (p < 0.05) those in the atorvastatin group. At the univariate analysis, no significant correlation was found between serum levels of either total cholesterol or HDL cholesterol and FMD. The nitroglycerin-induced dilation was not significantly influenced by extracorporeal circulation as well as by atorvastatin treatment. Conclusions: The endothelial dysfunction following cardiopulmonary bypass is improved by the treatment with atorvastatin, by a mechanism unrelated to the drug efficacy of controlling serum cholesterol levels. 相似文献
8.
目的:观察阿托伐他汀对系膜增殖性肾炎(MsPGN)大鼠肾组织细胞外基质(ECM)和纤溶酶原激活剂抑制物-1(PAI-1)表达的影响,探讨其肾脏保护作用的机制。方法:采用抗胸腺细胞血清诱发的MsPGN大鼠模型,将SD大鼠随机分为正常对照组、肾炎模型组、小剂量阿托伐他汀治疗组(8mg·kg^-1·d^-1)和大剂量阿托伐他汀治疗组(16mg·kg^-1·d^-1)。治疗12d后。检测各组大鼠血总胆固醇(CHOL)、甘油三酯(TG)、血肌酐(Scr)和24h尿蛋白,以及肾组织Ⅳ型胶原(Col Ⅳ)、纤维结合蛋白(FN)和PAI-1的表达。结果:阿托伐他汀治疗组大鼠24h尿蛋白、肾组织Col Ⅳ、FN和PAI-1 mRNA的表达明显下降。肾组织病理改变明显改善,与模型组相比有统计学差异(P〈0.05),且呈剂量依赖关系。其中肾炎模型组尿蛋白(30.34±0.62)mg/d。阿托伐他汀小剂量治疗组(21.17±0.79)mg/d,大剂量治疗组(9.77±0.54)mg/d。同时,各组血脂水平无明显差异(P〉0.05)。结论:阿托伐他汀可显著改善MsPGN大鼠肾脏病变,抑制肾组织ECM成分和PAI-1的表达。 相似文献
9.
O. A. Aswania S. A. Corlett H. Chrystyn 《European journal of clinical pharmacology》1998,54(6):475-478
Objective: To determine the effects of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of atorvastatin, a 3-hydroxymethylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor.
Methods: Twelve healthy subjects participated in a randomized two-way crossover study. Each subject received atorvastatin 10 mg every
morning for 2 weeks and atorvastatin 10 mg every morning with cimetidine 300 mg four times a day for 2 weeks, separated by
a 4-week washout period. Steady-state pharmacokinetic parameters (based on an enzyme inhibition assay) and lipid responses
were compared.
Results: Pharmacokinetic parameters and lipid responses were similar following administration of atorvastatin alone and atorvastatin
with cimetidine. Mean values for Cmax (the maximum concentration) were 5.11 ng · eq · ml−1 and 4.54 ng eq · ml−1, for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0–24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq · h · ml−1 and 58.5 ng eq · h · ml−1, and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with
cimetidine. Following treatment with atorvastatin alone and atorvastatin with cimetidine, mean values for the percentage change
from baseline for total cholesterol were −29.5% and −29.9%, for low-density lipoprotein (LDL) cholesterol −41.0% and −42.6%,
for high-density lipoprotein (HDL) cholesterol 6.3% and 5.8%, and for triglycerides −33.8% and −25.8%, respectively.
Conclusions: The rate and extent of atorvastatin absorption and the effects of atorvastatin on LDL-cholesterol responses are not influenced
by coadministration of cimetidine.
Received: 17 February 1997 / Accepted in revised form: 3 November 1997 相似文献
10.
背景 既往研究显示ACAT-1 rs1044925单核苷酸多态性(SNP)与冠心病及缺血性脑卒中的发病风险相关,并且与血脂水平有关。目的 本研究旨在探讨ACAT-1 rs1044925 SNP与急性冠脉综合征(ACS)的关系,以及rs1044925 SNP与ACS患者阿托伐他汀治疗后调脂效果的关系。方法 选择2016年1月—2018年1月在广西壮族自治区人民医院老年心血管内科确诊为ACS并接受经皮冠状动脉介入治疗(PCI)的患者111例作为ACS组(男67例,女44例);患者均接受阿托伐他汀治疗,20 mg/晚;同时服用氯吡格雷75 mg,1次/d(或替格瑞洛90 mg,2次/d),阿司匹林100 mg,1次/d;并在经PCI后常规使用阿托伐他汀,20 mg/晚。对照组为同期体检健康人群,共338例(男170例,女168例)。通过聚合酶链反应和限制性片段长度多态性(PCR-RFLP)对ACAT-1 rs1044925 SNP进行基因分型,检测ACS组和对照组的基线血脂水平,随访检测ACS组患者阿托伐他汀治疗1年后血脂参数。结果 ACS组和对照组受检者的血清总胆固醇(TC)间差异无统计学... 相似文献